The Neuro-Immune-Barrier Axis in Atopic Dermatitis: Pathophysiologic Insights and Targeted Therapeutic Breakthroughs

Abstract

Atopic dermatitis (AD) is an inflammatory skin condition that lasts for a long time and causes the skin's protective barrier to break down, leading to immune dysregulation and constant itching. In this review, we look at the neuro-immune-barrier axis that is involved in the development of Atopic dermatitis (AD), specifically at abnormalities in the barrier, type 2 inflammation, microbial dysbiosis, and neuronal sensitization. Flaws in filaggrin, epidermal lipids, and tight junctions elevate transepidermal water loss and promote allergen infiltration. Epithelial alarmins facilitate type 2 immune responses, especially through interleukin (IL)-4 and IL-13, whereas IL-31 and additional neuroimmune factors play a role in persistent pruritus and the itch-scratch cycle. The proliferation of Staphylococcus aureus intensifies inflammation and compromises barrier integrity. Targeted treatments, such as biologics and Janus kinase inhibitors, have enhanced disease management; nevertheless, ongoing pruritus, inconsistent treatment outcomes, and long-term safety issues persist. Innovative approaches, including aryl hydrocarbon receptor agonists, OX40/OX40L-targeted treatments, microbiome-centric interventions, and biomarker-driven precision medicine, could present novel therapeutic avenues. Improving long-term disease control and patient quality of life and supporting the development of personalized treatments could be achieved by understanding the interactions between neural, immune, microbial, and epidermal components.